Cas:66521-38-8 Melatonin D5 manufacturer & supplier

Chemical Name:Melatonin D5

CAS.NO:66521-38-8

Synonyms:N-[1,1,2,2-tetradeuterio-2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide

Molecular Formula:C₁₃H₁₂D₄N₂O₂

Molecular Weight:236.30300

HS Code:

Physical and Chemical Properties:

Melting point:117-118ºC

Boiling point:512.831ºC at 760 mmHg

Density:1.196g/cm3

Index of Refraction:1.6

PSA:54.12000

Exact Mass:236.14600

LogP:2.24600

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-[1,1,2,2-tetradeuterio-2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-[1,1,2,2-tetradeuterio-2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-[1,1,2,2-tetradeuterio-2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide Use and application,N-[1,1,2,2-tetradeuterio-2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide technical grade,usp/ep/jp grade.

Related News: Biogen’s Alzheimer’s drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug. dimethyl 2-(2-hydroxy-2-phenylethyl)-4-(3-hydroxyphenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate manufacturers During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031. 5-(3,4-dimethoxyphenyl)-N-(pyridin-3-yl)-7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide suppliers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. (R)-2-Amino-3-(4-methyl-2-nitro-phenylsulfanyl)-propionic acid vendor & factory During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031.,Biogen’s Alzheimer’s drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug.